You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Telehealth companies Noom, Found, and Hims & Hers have all recently launched programs to prescribe “microdosed” GLP-1s. The companies say that in small doses the drugs can provide myriad health benefits, but as Katie Palmer reports, there’s no robust evidence of these marketing claims. The strategy is the latest effort by telehealth companies and their compounding pharmacy partners to extend the runway to profit off of the popular diabetes and obesity drugs.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply